Navigation Links
PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/11/2007

- Data Presented at 36th Child Neurology Society Annual Meeting -

SOUTH PLAINFIELD, N.J., Oct. 11 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced pharmacokinetic and safety data from a Phase 2 clinical trial of PTC124 in patients with Duchenne muscular dystrophy (DMD) due to a nonsense mutation. The results, which include data from the third and final cohort of the study, show that treatment with PTC124 appeared well tolerated at all three dose levels and target plasma concentrations were achieved at the mid- and high-dose levels. These data were presented today at the 36th Annual Meeting of the Child Neurology Society (CNS) in Quebec City, Canada.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

In the study, patients received 28 days of PTC124 treatment at one of three dose levels. All clinical trial participants are boys with a nonsense mutation in the dystrophin gene, substantially elevated serum creatine kinase levels, and symptoms associated with DMD. The analysis presented today showed that PTC124 appeared well tolerated among the 38 boys included in the study. Adverse events were infrequent, mild to moderate in severity, and did not result in therapy interruptions or discontinuations. There were no concerns based on physical examinations, vital sign measurements, electrocardiograms or laboratory parameters. Compliance with PTC124 treatment was excellent at all three dose levels. Target plasma concentrations associated with activity in a preclinical model of DMD were achieved at the mid- and high-dose levels.

"DMD is a disorder with a significant need for better treatment options and we are encouraged by the results we have seen to date with PTC124," said Brend
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/256szd/corporate ) ... of Pharma in 2014 - a Perspective of Mental ... their offering. For the first time, in ... reputation of the pharmaceutical industry held by patient groups ... of patient organisations representing all therapy areas. ...
(Date:4/16/2015)... 2015 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for the treatment of central ... for the first quarter of 2015 on Wednesday, May ... The Company will host a conference call at 4:30 ... Vanda management will discuss the first quarter 2015 financial ...
(Date:4/16/2015)... April 16, 2015  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... 31, 2015 on Wednesday, May 6, 2015, following the close ... an investor conference call and live webcast on the same ... update and discuss the financial results.  To ... , under the "Investors" link.  Please log onto the webcast ...
Breaking Medicine Technology:Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3
... on Valopicitabine Combined,with an Investigational Protease Inhibitor, ... Pharmaceuticals, Inc. today announced results from two ... valopicitabine (NM283) and,pegylated interferon alfa-2a (Pegasys(R)) in ... the genotype-1,strain of the hepatitis C virus ...
... /PRNewswire-FirstCall/ --,CuraGen Corporation announced today that new ... (HDAC) inhibitor being,investigated for the treatment of ... the prevention of severe oral mucositis,will be ... Cancer,Research (AACR) 2007 Annual Meeting in Los ...
Cached Medicine Technology:Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4
(Date:4/19/2015)... Broccoli sprout extract protects against oral cancer in ... healthy human volunteers, the University of Pittsburgh Cancer ... announced today at the American Association for Cancer ... The promising results will be further explored in a ... risk for head and neck cancer recurrence later this ...
(Date:4/19/2015)... 2015 New court documents issued by ... that Lipitor lawsuits ( http://www.lipitorlawsuitcenter.com/ ) continue to mount ... District of South Carolina. According to the April 15th ... in the proceeding on behalf of individuals who allegedly ... the cholesterol-lowering statin. This represents an increase of 110 ...
(Date:4/19/2015)... (PRWEB) April 19, 2015 Family and friends ... for Brains in Memory of Brad Baddeley event to ... Aneurysm Foundation. , Bowling for Brains is cheduled to take ... 4700 Dudley Street in Lincoln, Nebraska. Participants may arrive at ... to 3:00pm. , The cost is only $4 per game ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 Carinsurancequotesinfo.com has ... insurance can cover physical injuries caused by a ... excellent financial coverage for a vehicle. A policy can ... by an accident. Drivers should always carry appropriate coverage ... insurance policy can be bought with several important riders ...
(Date:4/18/2015)... Review of Ophthalmology magazine and Abbot ... Success’ program for cataract surgeons attending the American Society ... where eye surgeon Jeffrey L. Martin, MD will serve ... Martin is the Managing Partner of North Shore Eye ... Martin to lead this year’s discussion on the latest ...
Breaking Medicine News(10 mins):Health News:Preventing Cancer with Broccoli Sprout Extract 2Health News:Preventing Cancer with Broccoli Sprout Extract 3Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 2Health News:Lipitor Lawsuits Mount, as New Court Report Shows More Than 100 Filings Added to Federal Litigation Since March 3Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 2Health News:Lincoln, NE’s Bowling for Brains to benefit Renowned Brain Aneurysm Foundation 3Health News:Auto Insurance Plans Can Cover Physical Injuries Caused By An Accident! 2Health News:Dr. Jeffrey Martin Invited to Share Latest Breakthroughs in Cataract Care During Roundtable Discussion at National 2015 ASCRS Meeting In San Diego 2
... ULURU Inc. (Amex:,ULU) announced today that its ... Back Offer, whereby the Company will offer to ... shares of common stock. This,program reflects ULURU,s desire ... communications costs and the potential costs,which often deter ...
... may actually be in the candy dish. In ... Heart Association conference in Orlando shows that people at ... kept the wrappers in plain sight The sneakiest, creepiest surprise ... In a study being presented this Saturday ...
... almost half of patients, study found , TUESDAY, Oct. 30 ... for treating people with what,s known as cytokine-refractory metastatic kidney ... poor response to drug treatment. , Axitinib is a selective ... receptors 1, 2 and 3. , As reported in ...
... Pa., Oct. 30 ViroPharma Incorporated,(Nasdaq: VPHM ) reported today ... 2007. Key events since June 30, 2007 include:, Clinical:, ... Camvia(TM) (maribavir) in liver transplant patients; ... of Camvia in stem cell transplant patients; ...
... TORONTO, Oct. 30 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer ... room, will host a conference call and live webcast,to discuss the ... ... 4:30 pm, Eastern Time, Dial ...
... Oct. 30 GeneGo, Inc., the leading,systems biology ... its flagship data analysis suite MetaCore(TM). The platform,will ... is designed for,functional analysis of biological and chemistry ... autoimmune programs. "We are very pleased that ...
Cached Medicine News:Health News:ULURU Inc. Announces Odd-Lot Buy Back Offer 2Health News:Food 'tricks' that combat sneaky, creepy Halloween treats 2Health News:New Drug Promising Against Tough-to-Treat Kidney Cancer 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results 10Health News:Novadaq announces third quarter 2007 conference call and webcast 2Health News:Novadaq announces third quarter 2007 conference call and webcast 3
... This test device is ... detection of IgG and IgM ... human serum. The test is ... for diagnosis of Dengue viral ...
... Gonorrhea is intended for the immunochromatographic, ... swab samples.,Smart Strip Gonorrhea is based ... for the determination of gonorrhea antigen ... from urinary system as an aid ...
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: